Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
Anti-inflammatory dimethylfumarate: a potential new therapy for asthma?
Episode 14 with Professor Gavin Giovannoni on the Epstein-Barr Virus (EBV).
JOINT CONGRESS OF EUROPEAN NEUROLOGY
Association between beta-interferon exposure and hospital events in multiple sclerosis.
Antibody to α4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis.
Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.
The employment concerns of Americans with multiple sclerosis: Perspectives from a national sample.
European Commission approves Genzyme’s multiple sclerosis treatment Lemtrada™ (alemtuzumab)
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.
Self-assembling nanocomplexes by combining ferumoxytol, heparin and protamine for cell tracking by magnetic resonance imaging.
Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis.
Microglia in health and disease.
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
You-Gui pills promote nerve regeneration by regulating netrin1, DCC and Rho family GTPases RhoA, Racl, Cdc42 in C57BL/6 mice with experimental autoimmune encephalomyelitis.
Interferon beta-1b
The mediating role of processing speed in the relationship between depressive symptoms and cognitive function in multiple sclerosis.
Neuroimmunomodulation by allogeneic seminal vesicle fluid in CNS is sex-independent.
The effectiveness of dimethyl fumarate monotherapy in the treatment of relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.
Acute disseminated encephalomyelitis in 228 patients: A retrospective, multicenter US study.
Neuroimmunology: Phase II trial demonstrates efficacy of erythropoietin in optic neuritis.
AAN: Annual Meeting On Demand Encore: Treatment Optimization for Relapsing MS
Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis.
Effect of smoking on multiple sclerosis: a meta-analysis.
ASNI Calgary 2015
Pages
« first
‹ previous
…
63
64
65
66
67
68
69
70
71
…
next ›
last »